[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"temporomandibular-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:temporomandibular-disorders":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,74,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100639578","three-photobiomodulation-wavelengths-635-940-and-1064-nm-on-chronic-myogenic-temporomandibular-disorder-100639578",false,"NCT07626164","Three Photobiomodulation Wavelengths (635, 940, and 1064 nm) on Chronic Myogenic Temporomandibular Disorder","Efficacy of Three Photobiomodulation Wavelengths (635, 940, and 1064 nm) on Chronic Myogenic Temporomandibular Disorder A Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients suffering from chronic myogenic TMD based on diagnostic criteria for diagnosis of temporomandibular joint disorders (DC\u002FTMD) criteria. (pain increases with jaw opening, chewing, or clenching).\n* Patients suffering of unilateral or bilateral chronic pain (\\> 3 months' duration) related to masseter and temporalis muscles(30).\n* Patients suffering of moderate-to-severe pain intensity ≥ 4 on a 0-10 VAS\n* Patients that have not responded to conservative modes of treatment during the study and up to 3 months after last intervention. (medications, physiotherapy, splints).\n\nExclusion Criteria:\n\n* Patients suffering from chronic systematic conditions that alter pain sensitivity; neurological diseases, pain of dental origin, pregnancy or lactation, high blood pressure, diabetes milletus, rheumatic inflammatory disease, fibromyalgia, obstructive sleep apnea, and restrictions for the use of laser (pacemakers).\n* Participants on medications that affect pain sensitivity and perception during the last 2 weeks: anticoagulants, analgesics, or antidepressants.\n* History of surgery, arthropathy (joint disorders), facial trauma, malignant tumors or fractures in the orofacial region, neuropsychological or hormonal problems\n* Treatments: orthodontics, splints, major occlusal rehabilitation, prosthodontic therapy, previous PBM, TENS therapy, or botox for TMD in the last 6 months.","ALL","20 Years","50 Years",{"count":20,"type":21},45,"ESTIMATED","INTERVENTIONAL",[24],"NA","Temporomandibular disorders (TMDs) are among the most common musculoskeletal conditions associated with chronic orofacial pain and functional disability. Chronic Myogenic TMD (MTMD) is the most prevalent subtype and is characterized by persistent masticatory muscle pain driven by peripheral and central sensitization mechanisms. Photobiomodulation (PBM) represents a conservative, non-invasive therapeutic modality within the medical management of TMD; however, the wavelength-dependent clinical and muscular effects remain inadequately defined. Aim: To compare the efficacy of three PBM wavelengths (635, 940, 1,064 nm) on pain intensity, mandibular function, surface electromyographic activity (sEMG), and pressure pain threshold (PPT) in patients with chronic myogenic TMD.",[27],"Temporomandibular Disorders","NOT_YET_RECRUITING","2026-06-02",{"date":31,"type":32},"2026-06-04","ACTUAL",{"date":34,"type":21},"2026-06-01",{"date":36,"type":21},"2026-12-30",{"name":38,"class":39},"Alexandria University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":40},"100494583","phase-2-peripheral-tmd-pain-mechanisms-and-the-effect-by-botulinum-toxin-a-100494583","NCT05720065","Peripheral TMD Pain Mechanisms and the Effect by Botulinum Toxin A","Peripheral TMD Pain Mechanisms and the Effect by Botulinum Toxin A. A Randomized, Controlled, Double-blind Study","Inclusion Criteria:\n\n* a diagnosis of TMDM myalgia or myofascial pain according to the DC\u002FTMD criteria\n* females with adequate contraceptives and a negative pregnancy test\n* pain upon digital palpation of at least one of the masseter muscle\n* a characteristic pain intensity of \\> 40\u002F100\n* a negative pregnancy test at the day of treatment\n\nExclusion Criteria:\n\n* difficulties understanding the Swedish language\n* systemic inflammatory connective tissue diseases\n* widespread pain\n* neuromuscular disorders\n* diagnosed or severe psychiatric disease\n* neuropathic pain\n* pain of dental origin\n* history of trauma to the face, head or neck\n* pregnancy or nursing\n* known allergy to botulinum toxin or antibiotics\n* use of muscle relaxants, antidepressant, neuropsychiatric, anticoagulant drugs, or aminoglycoside antibiotics\n* previous treatment with botulinum toxin during the last 12 months\n* use of analgesic or anti-inflammatory medication during the 48 hours preceding biopsy\n* skin infection over injection\u002Fbiopsy site","FEMALE","45 Years",{"count":51,"type":21},50,[53],"PHASE2","The goal of this clinical trial is to investigate the effect of botulinum toxin on neurons' plasticity in the masseter muscle in humans with and without painful myogenous temporomandibular disorders (TMDM). The main questions it aims to answer are:\n\n* does treatment with botulinum toxin alter gene expressions, epigenetic signatures, and cells plasticity in the masseter muscles of TMDM patients?\n* do any such changes differ between patients with local and regional TMDM?\n* does treatment with botulinum toxin influence pain characteristics (intensity, frequency, and sensibility) and other variables in patients with TMDM and are there correlations between significantly changed expression of biomarkers and other variables?\n\nParticipants will be examined with a questionnaire, clinical examination (including quantitative sensory testing; QST), and microbiopsy sampling from one of the masseter (MM) and anterior tibialis (AT) muscles and are then randomized to treatment with botulinum toxin or control (isotonic saline). Follow-ups occur after one and three months for all patients, and six months with questionnaire, clinical examination, and collection of post-treatment microbiopsies to see if botulinum toxin alter peripheral molecular events and clinical variables.",[27],[27,57,58,59,60,61,62,63],"Botulinum Toxin A","Myalgia","Randomized","Clinical Trial","Pain","Gene","Neural Plasticity","RECRUITING","2025-02-13",{"date":67,"type":32},"2025-02-17",{"date":69,"type":32},"2023-09-20",{"date":71,"type":21},"2027-08-31",{"name":73,"class":39},"Karolinska Institutet",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":40},"100560821","effectiveness-of-brief-mindfulness-based-interventions-for-painful-temporomandibular-disorders-among-university-students-100560821","NCT06582134","Effectiveness of Brief Mindfulness-Based Interventions for Painful Temporomandibular Disorders Among University Students","Effectiveness of Brief Mindfulness-Based Interventions (BMBI) for Painful Temporomandibular Disorders (TMD) Among University Students","Inclusion Criteria:\n\n* Students attending Universiti Malaya\n* Able to read and understand English.\n* Willing and able to give informed consent.\n* Score 3 and above on the TMD-PS, for at least 3 months.\n\nExclusion Criteria:\n\n* Hearing impairment.\n* Currently on psychiatric follow up and\u002For taking psychotropic prescriptions (antidepressants, anti-anxiety medications, stimulants, antipsychotics, and mood stabilizers).\n* Experience with activities similar to the intervention such as meditation, yoga or tai chi.\n* Currently practicing some form of mindfulness meditation.\n* History of orofacial trauma, craniofacial pathology, and previous orofacial surgeries (including orthognathic and TMJ)\n* Systemic rheumatic, neurologic\u002Fneuropathic, endocrine (e.g., diabetes mellitus) or immune \u002F autoimmune diseases or widespread pain or being treated with immunosuppressant drugs\n* Non-TMD orofacial pain disorders\n* Radiation treatment to head and neck.\n* Use of narcotic pain medication, muscle relaxants or steroid therapy unless discontinued 1 week before enrolment to study\n* Use of nonsteroidal anti-inflammatory medications unless the medication(s) were discontinued for 3 days prior to enrolment (use of acetaminophen is allowed as a rescue drug)\n* Currently on antibiotics or taken antibiotics within the last 2 weeks prior to start of study\n* Currently pregnant or lactating women","18 Years","30 Years",{"count":51,"type":21},[24],"The goal of this clinical trial is to learn if brief mindfulness-based intervention (BMBI) is beneficial to participants suffering from painful temporomandibular disorders (TMD). The objectives of the research are:\n\n1. To compare physical functioning (pain intensity and jaw function) in UM students with chronic pain-related TMD before and after receiving BMBI\n2. To compare psychological distress and mindfulness state in UM students with chronic pain-related TMD before and after receiving BMBI\n3. To compare the quality of life of UM students with chronic pain-related TMD before and after receiving BMBI\n4. To compare the changes in physical functioning, psychological distress, mindfulness state and quality of life between UM students in the intervention (BMBI) and the control groups.\n\nParticipants will:\n\nListen to the audio recordings 3 times a week, for 3 months when they are about to sleep.\n\nMake 4 visits to the clinic: Baseline, 2 weeks, 1 month and 3 months later.",[27,87],"Chronic Pain",[89,90,91],"Brief mindfulness-based intervention","Temporomandibular disorders","University students","2024-08-30",{"date":94,"type":32},"2024-09-04",{"date":96,"type":32},"2024-01-12",{"date":98,"type":21},"2025-09",{"name":100,"class":39},"University of Malaya",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":122,"leadSponsor":124,"locationsCount":40},"100558655","mandibular-splint-vs-botox-injection-in-lateral-pterygoid-on-cervical-muscle-activity-in-patients-with-temporomandibular-disorders-100558655","NCT06553950","Mandibular Splint vs Botox Injection in Lateral Pterygoid on Cervical Muscle Activity in Patients With Temporomandibular Disorders","Mandibular Splint Versus Botox Injection in Lateral Pterygoid on Cervical Muscle Activity in Patients With Temporomandibular Disorders","Inclusion Criteria:\n\n* Age from 18-40 years old.\n* Both sexes.\n* Duration of the disease is more than 3 months.\n* Anterior mandibular disc displacement with reduction will be included.\n* Unilateral anterior mandibular displacement with reduction grade 2\\&3 (Wilkes) will be included.\n* Patients with cervical muscles spasm and trigger points (upper trapezius\\& sternocleidomastoid) will be included.\n* Patients with sufficient cognitive abilities that enables them to understand and follow instructions.\n\nExclusion Criteria:\n\n* Neurological or musculoskeletal diseases that affect cervical spine other than mandibular disc displacement (eg: cervical spondylosis, spondylolisthesis, and cervical disc injuries)\n* Bilateral anterior mandibular disc displacement patients.\n* Musculoskeletal disorders such as severe arthritis, cervical spine surgery or contractures of fixed deformity, leg length discrepancy.\n* women during pregnancy and lactation.\n* Patients with known hypersensitivity to any component of the drug (especially hypersensitivity to human albumin).\n* Patients with infection or inflammation of the area where the toxin injections are planned, in patients with musculoskeletal conduction disorders, in primary muscular disorders (muscular dystrophy, neuromyopathy, congenital myopathies, myotonic disorders, mitochondrial myopathy and unspecified or other primary muscle disorders).\n* Patients being treated with aminoglycoside antibiotics, ciclosporin, D-penicillamine, tubocurarine, pancuronium, gallamine, succinylcholine, chloroquine, or hydroxychloroquine.\n* History of cervical spine surgery.\n* History of trauma or fractures in cervical spine.\n* Signs of cervical radiculopathy or myelopathy.\n* Vascular syndrome such as vertebrobasilar insufficiency.\n* Signs of serious pathology ( e.g., malignancy, inflammatory disorders, infection).","40 Years",{"count":110,"type":21},33,[24],"The study aims to compere mandibular splint versus botox injection in lateral pterygoid on cervical muscle activity in patients with temporomandibular disorders",[114,115,116,117,27],"Mandibular Splint","Botox","Lateral Pterygoid","Cervical Muscle Activity","2024-08-14",{"date":120,"type":32},"2024-08-16",{"date":118,"type":32},{"date":123,"type":21},"2025-02-01",{"name":125,"class":39},"Cairo University"]